What is a potential benefit of a modified form of EPO in stroke treatment?

• A. Increased blood viscosity
• B. Preventing apoptosis in CNS without increasing blood viscosity
• C. Enhancing erythrocyte production
• D. Promoting blood clotting

Answer: (B)

A modified form of erythropoietin (EPO) in stroke treatment is beneficial because it can prevent apoptosis in the central nervous system (CNS) without increasing blood viscosity. In the context of stroke, reducing cell death in brain tissues is critical for preserving neurological function and promoting recovery.

Standard EPO primarily stimulates erythrocyte production, which can lead to increased blood viscosity, especially in the aftermath of a stroke when blood flow and oxygen delivery to the brain are of utmost importance. High blood viscosity can complicate recovery and exacerbate ischemia.

The modified form of EPO can focus on its neuroprotective effects. It can exert benefits such as reducing inflammation and apoptosis in neurons and glial cells, thus helping to mitigate secondary damage following a stroke.

Other potential answers involve enhancing erythrocyte production or promoting blood clotting, which may not directly address the neurological aspects of a stroke and could lead to complications. Therefore, the selected benefit of preventing apoptosis while avoiding the adverse effects associated with increased blood viscosity aligns well with the therapeutic goals in stroke management.